Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 196   

Articles published

SNY 51.85 +0.67 (1.31%)
price chart
Sanofi To Sell Mature Drugs Portfolio
Sanofi SA (ADR) (SNY) wishes to divest its portfolio of old drugs whose patents have expired or are due to expire. As per a document circulated by the CGT labor union, the Paris-based pharmaceutical company plans to divest 200 mature products from its ...
Related articles »  
For Sanofi SA (ADR) (SNY) Chronic Diseases Present the Future Focus
In an interview with CNBC, Chris Viehbacher, the CEO of Sanofi SA (ADR) (NYSE:SNY), discussed the steps that big pharma companies like Sanofi SA (ADR) (NYSE:SNY) are taking to tackle chronic diseases that are a major cause of worry for the aging ...
Related articles »  
FDA Accepts Sanofi's NDA For Toujeo
Sanofi SA (SNY) announced today that the US Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for its experimental therapy drug, Toujeo.
Related articles »  
Investor's Watch List - Sanofi SA (ADR) (SNY), XOMA Corp (XOMA), AVEO ...
Birmingham, West Midlands - (TechSonian) �July 12, 2014 - Sanofi SA (ADR) (NYSE:SNY) declared the positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic ...
Related articles »  
Stocks On the move: Sanofi SA (ADR) (NYSE:SNY), Forest Laboratories (NYSE ...
Sanofi SA (NYSE:SNY) had its neutral rating reissued by analysts at Zacks. The firm currently has a $57.00 target price on the stock.
Related articles »  
Stock Alert: Sanofi SA (ADR) (NYSE:SNY), Amgen (NASDAQ:AMGN), Bio-Rad ...
Co and Sanofi SA (ADR) (NYSE:SNY) announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD.
Notable Stocks: Merck & Co. (NYSE:MRK), Sanofi SA (ADR) (NYSE:SNY), Eli ...
This third party may exploit these patent rights independently or in conjunction with another third party. On last trading day, Sanofi SA (ADR) (NYSE:SNY)'s stock traded at beginning with a price of $53.30 and throughout the trading session climbed at ...
Sanofi SA Upgraded to "Outperform" by Mainfirst (SNY)
Sanofi SA (ADR) logo Sanofi SA (NYSE:SNY) was upgraded by Mainfirst to an �outperform� rating in a research note issued on Monday.
Related articles »  
Versatile News at Street: Pearson (NYSE:PSO), Vodafone (NASDAQ:VOD ...
In last trading session, shares of Sanofi SA (ADR) (NYSE:SNY) fell -2.04%, closing the day at $50.97, after wavering among $50.83 and $51.73 during the trading session.
Related articles »  
Drug Stocks: Impax Laboratories Inc (NASDAQ:IPXL), Retrophin Inc (NASDAQ ...
On 20 JUNE Sanofi SA (ADR) (NYSE:SNY) reported $0.81 earnings per share for the quarter, missing the analysts' consensus estimate of $0.84 by $0.03.